elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Pneumonitis
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Pneumonitis
RIS
0.001
(Research Intensity Score)
Papers
284
Top papers
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
2025 · 115 citations
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
2025 · 45 citations
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
2025 · 52 citations
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
2023 · 115 citations
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial
2023 · 90 citations
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group
2023 · 84 citations
The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement
2019 · 453 citations
Systemic Lupus Erythematosus and Lung Involvement: A Comprehensive Review
2022 · 73 citations
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab
2025 · 15 citations
Newest papers
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
2026 · 2 citations
Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: a single-center retrospective study
2026
Primed to React: Neutrophil‐To‐Lymphocyte Ratio to Predict Severe Checkpoint Inhibitor Pneumonitis
2026
The real-world safety profile of enfortumab vedotin with or without pembrolizumab: insights from a comparative analysis of FAERS
2026
Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer: the durvalumab expanded access cohort
2026
Precision Stereotactic Body Radiotherapy for Ultra‐Central NSCLC: Tailored Margins Reduce Toxicity Without Compromising Tumor Control
2026
When Vomiting Is More Than a Hangover: A Near-Missed Boerhaave Syndrome
2026
Consolidative versus salvage stereotactic ablative radiotherapy to the primary lung tumor in stage IV non–small cell lung cancer
2026
Treatment Outcomes for Elderly Patients over the Age of 70 with Early-Stage Peripheral Non-Small Cell Lung Cancer Who Were Treated with Stereotactic Body Radiation Therapy (SBRT) at a Total Dose of 55 Gy in Four Fractions: A Single-Institution Retrospective Study
2026
Browse all papers →
Pneumonitis's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Pneumonitis's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link